Public Market Listing
ZYDUSLIFENSE
Live quotes, historical charts, and market capitalization for Zydus Lifesciences are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
3Total Assets
1Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Ranibizumab(Lucentis) | Approved | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration |
Desidustat(Oxemia) | Phase 3 | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
Saroglitazar(Lipaglyn) | Phase 3 | PPAR-alpha/PPAR-gammaSmall molecule | Indication not yet linked |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.